ADC

77개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved77 programs
ADCStandard DatabasestalePfizerPhase 3

Inotuzumab ozogamicin (Inotuzumab ozogamicin)

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 53Status Recruiting
ADCLimited DatastaleGSKPhase 2

Belantamab (Belantamab)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#ADC#Phase2#Popular#antibody-drug-conjugate+2
Trials 52Status Recruiting
ADCStandard DatabasestaleRochevedotin, rituximab, cycloph…Phase 2

Polatuzumab (Polatuzumab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 52Status Recruiting
ADCStandard DatabasestaleSeagenvedotin-containing regimen …Phase 2

Adcetris (Brentuximab vedotin, Brentuximab vedotin (Adcetris))

Anaplastic Large Cell Lymphoma, ALK-Positive · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 51Status Recruiting
ADCLimited DatastaleBristol-Myers SquibbPhase 2

Luspatercept (Luspatercept)

Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 51Status Recruiting
ADCLimited DatastaleAstellas Pharma Incvedotin after avelumabPhase 1

Enfortumab (Enfortumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#antibody-drug-conjugate#vedotin+2
Trials 49Status Active
ADCStandard DatabasestaleADC TherapeuticsPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+2
Trials 48Status Recruiting
ADCStandard DatabasestaleAstellasPhase 3

EV/P (enfortumab vedotin and pembrolizumab, enfortumab vedotin and pembrolizumab (EV/P))

Advanced Bladder Cancer · Advanced Bladder Cancer

#AdvancedBladderCancer#ADC#Phase3#antibody-drug-conjugate#ADCsandimmunotherapyhavechangedt+1
Trials 47Status Recruiting
ADCLimited DatastaleCSPC ZhongQi Pharmaceutical Tec…Phase 1

an antibody drug conjugate (an antibody drug conjugate)

Neoplasms · Neoplasms

#Neoplasms#ADC#Phase1#antibody-drug-conjugate#CSPC
Trials 31Status Active
ADCStandard DatabasestaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCStandard DatabasestaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
ADCStandard DatabasestaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 13Status Recruiting
ADCStandard DatabasestaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 12Status Recruiting
ADCStandard DatabasestaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active

2 / 4 pages

← PreviousNext →